Parallel Group Comparison(平行组比较)研究综述
Parallel Group Comparison 平行组比较 - METHODS In this prospective, multicenter, open-label, randomized, parallel-group comparison study, 162 patients with T2DM and one or more metabolic risk factors were randomized into a teneligliptin or canagliflozin group and treated for 24 weeks. [1] METHODS This multicenter (n=13), randomized, active-controlled, colonoscopist- and image evaluator-blinded, noninferiority study with parallel-group comparison recruited 632 patients from December 2018 to June 2019. [2] Methods: This single-blinded (investigator-blinded) parallel-group comparison study was conducted on women with a tendency toward constipation and subjective symptoms of dry skin. [3] Patients and Methods We conducted a prospective parallel-group comparison study on 195 eligible residents from Takahata, Japan, with a high risk of lifestyle-related diseases from 2014 to 2017 to examine whether such an intervention could improve the body mass index (BMI) and estimated glomerular filtration rate (eGFR). [4] Previous studies reporting devices usage have not undertaken prospective parallel-group comparisons before their introduction, so the comparative differences are unknown. [5] METHODS This multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study was conducted at 20 institutions in Japan. [6] Methods : This was a randomized, placebo-controlled, double-blind, parallel-group comparison study involving 32 healthy Japanese adults with eye fatigue after using visual display terminals (VDTs). [7] Previous studies reporting devices usage have not undertaken prospective parallel-group comparisons before their introduction, so the comparative differences are unknown. [8]方法 在这项前瞻性、多中心、开放标签、随机、平行组比较研究中，162 名患有一种或多种代谢危险因素的 T2DM 患者被随机分为特力列汀或卡格列净组，治疗 24 周。 [1] 方法 这项多中心 (n=13)、随机、主动对照、结肠镜检查和影像评估者双盲、非劣效性研究与平行组比较招募了 2018 年 12 月至 2019 年 6 月的 632 名患者。 [2] 方法：这项单盲（研究者盲）平行组比较研究针对有便秘倾向和皮肤干燥主观症状的女性进行。 [3] 患者和方法 我们对 2014 年至 2017 年来自日本高畑的 195 名符合条件的居民进行了一项前瞻性平行组比较研究，这些居民患有生活方式相关疾病的高风险，以检验这种干预是否可以改善体重指数（BMI）和估计肾小球滤过率（eGFR）。 [4] 以前报告设备使用情况的研究在引入之前没有进行前瞻性平行组比较，因此比较差异是未知的。 [5] 方法 这项多中心、随机、双盲、安慰剂对照、平行组比较研究在日本的 20 家机构进行。 [6] 方法：这是一项随机、安慰剂对照、双盲、平行组比较研究，涉及 32 名使用视觉显示终端 (VDT) 后出现眼疲劳的健康日本成年人。 [7] 以前报告设备使用情况的研究在引入之前没有进行前瞻性平行组比较，因此比较差异是未知的。 [8]